Audentes Therapeutics Inc (BOLD):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Audentes Therapeutics Inc (BOLD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8283
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Audentes Therapeutics Inc (Audentes) is a biotechnology company that focuses on the development and commercialization of gene therapy products for serious and life-threatening rare diseases. The company’s pipeline products include AT132, intended for the treatment of X-linked myotubular myopathy; AT982, for the treatment of Pompe disease; AT342, for the treatment of crigler-najjar syndrome; and AT307, for the treatment of CASQ2-related catecholaminergic polymorphic ventricular tachycardia. Audentes offers viral vectors for gene therapy most frequently and track record off adeno-associated virus vector (AAV) in non-pathogenic product, among others. The company has collaboration with various patient, research and medical communities to advance its product candidates. Audentes is headquartered in San Francisco, California, the US.

Audentes Therapeutics Inc (BOLD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Audentes Therapeutics Raises USD65 Million in Series C Financing Round 12
Audentes Therapeutics Raises USD42.5 Million in Series B Financing 15
Cardiogen Sciences Secures USD0.52 Million in Venture Funding 17
Audentes Therapeutics Raises US$30 Million In Series A Financing 18
Audentes Therapeutics Raises Funds through Seed Financing 20
Partnerships 21
Audentes Therapeutics Amends Co-Development with University of Pennsylvania 21
Audentes Therapeutics Enters Into Co-Development Agreement With Genethon For AT001 22
Licensing Agreements 23
Audentes Therapeutics Enters Into Licensing Agreement With RegenxBio 23
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio for CPVT 24
Audentes Therapeutics Amends its Licensing Agreement with University of Florida Research Foundation 26
Cardiogen Sciences Enters into Licensing Agreement with Fondazione Salvatore Maugeri 27
Audentes Therapeutics Enters Into Licensing Agreement with ReGenX Biosciences 28
Equity Offering 29
Audentes Therapeutics Prices Public Offering of Shares for USD150.8 Million 29
Audentes Therapeutics Raises USD231 Million in Public Offering of Shares 31
Audentes Therapeutics to Raise up to USD75 Million in Public Offering of Shares 33
Audentes Therapeutics Raises USD86.3 Million in Public Offering of Shares 34
Audentes Therapeutics Raises USD75 Million in IPO 36
Acquisition 37
Audentes Therapeutics Acquires Cardiogen Sciences 37
Audentes Therapeutics Inc – Key Competitors 38
Audentes Therapeutics Inc – Key Employees 39
Audentes Therapeutics Inc – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Financial Announcements 41
Aug 07, 2018: Audentes Therapeutics Reports Second Quarter 2018 Financial Results 41
May 09, 2018: Audentes Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update 43
Mar 08, 2018: Audentes Therapeutics Announces Fourth Quarter 2017 And Full Year Financial Results 45
Nov 14, 2017: Audentes Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 46
Aug 10, 2017: Audentes Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update 47
May 11, 2017: Audentes Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update 49
Mar 09, 2017: Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 51
Jan 09, 2017: Audentes Therapeutics Provides Full Year 2017 Strategic Outlook and Financial Guidance 54
Corporate Communications 56
Oct 03, 2018: Audentes Therapeutics announces co-founder and chief executive Officer Matthew R. Patterson appointed chairman of the alliance for regenerative medicine 56
May 08, 2018: Audentes Therapeutics Announces the Promotion of Natalie Holles to President and Chief Operating Officer 57
Dec 13, 2017: Audentes Therapeutics Appoints Mark A. Goldberg, M.D. to its Board of Directors 58
Jun 13, 2017: Audentes Therapeutics Appoints Jennifer Jarrett to Board of Directors 59
May 08, 2017: Audentes Therapeutics Announces Appointment of John T. Gray, Ph.D. to Senior Vice President and Chief Scientific Officer 60
Product News 61
04/30/2018: Audentes Therapeutics Announces Presentation of Data at the 21st Annual Meeting of the American Society of Gene and Cell Therapy 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Audentes Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Audentes Therapeutics Raises USD65 Million in Series C Financing Round 12
Audentes Therapeutics Raises USD42.5 Million in Series B Financing 15
Cardiogen Sciences Secures USD0.52 Million in Venture Funding 17
Audentes Therapeutics Raises US$30 Million In Series A Financing 18
Audentes Therapeutics Raises Funds through Seed Financing 20
Audentes Therapeutics Amends Co-Development with University of Pennsylvania 21
Audentes Therapeutics Enters Into Co-Development Agreement With Genethon For AT001 22
Audentes Therapeutics Enters Into Licensing Agreement With RegenxBio 23
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio for CPVT 24
Audentes Therapeutics Amends its Licensing Agreement with University of Florida Research Foundation 26
Cardiogen Sciences Enters into Licensing Agreement with Fondazione Salvatore Maugeri 27
Audentes Therapeutics Enters Into Licensing Agreement with ReGenX Biosciences 28
Audentes Therapeutics Prices Public Offering of Shares for USD150.8 Million 29
Audentes Therapeutics Raises USD231 Million in Public Offering of Shares 31
Audentes Therapeutics to Raise up to USD75 Million in Public Offering of Shares 33
Audentes Therapeutics Raises USD86.3 Million in Public Offering of Shares 34
Audentes Therapeutics Raises USD75 Million in IPO 36
Audentes Therapeutics Acquires Cardiogen Sciences 37
Audentes Therapeutics Inc, Key Competitors 38
Audentes Therapeutics Inc, Key Employees 39
Audentes Therapeutics Inc, Subsidiaries 40

List of Figures
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Audentes Therapeutics Inc (BOLD):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Anthem, Inc.:企業の戦略・SWOT・財務情報
    Anthem, Inc. - Strategy, SWOT and Corporate Finance Report Summary Anthem, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Ziehm Imaging GmbH:医療機器:M&Aディール及び事業提携情報
    Summary Ziehm Imaging GmbH (Ziehm Imaging) is a medical device company that develops, produce and markets mobile X-ray based imaging solutions. The company's products include c-arms with flat panel detectors, c-arms with 3D imaging and c-arms with image intensifier. It offers Ziehm Vision RFD 3D, 3D …
  • Holding Slovenske elektrarne doo:企業の戦略的SWOT分析
    Holding Slovenske elektrarne doo - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Arsanis Inc (ASNS):製薬・医療:M&Aディール及び事業提携情報
    Summary Arsanis Inc (Arsanis) is a clinical-stage biopharmaceutical company that focuses on the development of monoclonal antibody immunotherapies for the treatment of critical infectious diseases. The company’s pipeline product portfolio includes ASN100, for staphylococcus aureus; ASN500, targets r …
  • Community Bank System Inc (CBU):企業の財務・戦略的SWOT分析
    Community Bank System Inc (CBU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Diplomat Pharmacy Inc (DPLO):製薬・医療:M&Aディール及び事業提携情報
    Summary Diplomat Pharmacy Inc (Diplomat Pharmacy) is a specialty pharmacy services provider that offers personalized medication therapies and various other clinical services. It also provides pharmacy benefit management and customized care management solutions, including dispensing, delivery, dosing …
  • Tendril Networks, Inc.:電力:M&Aディール及び事業提携情報
    Summary Tendril Networks, Inc. (Tendril) is a provider of cloud-based energy services management solutions. The company offers Energy Services Management platform that helps energy service providers meet energy efficiency goals across various channels including web, mobile, mail, and email; to enhan …
  • DiGi.Com Berhad (DIGI):企業の財務・戦略的SWOT分析
    DiGi.Com Berhad (DIGI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Stantec Inc (STN):電力:M&Aディール及び事業提携情報
    Summary Stantec Inc. (Stantec) is a construction and consulting services company. The company offers architectural, engineering, and environmental services. Its service portfolio includes architecture and interior design, building engineering, community design services, geomatics, geotechnical engin …
  • George Weston Limited (WN):企業の財務・戦略的SWOT分析
    George Weston Limited (WN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Midatech Pharma US Inc:企業の戦略的SWOT分析
    Midatech Pharma US Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • UGL Ltd:企業の戦略的SWOT分析
    UGL Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Nila Infrastructures Ltd
    Nila Infrastructures Ltd - Strategy, SWOT and Corporate Finance Report Summary Nila Infrastructures Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Tokyo Electron Ltd (8035):企業の財務・戦略的SWOT分析
    Tokyo Electron Ltd (8035) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Magnetek Inc:企業の戦略的SWOT分析
    Magnetek Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • H.I.G. Capital LLC:企業の戦略的SWOT分析
    H.I.G. Capital LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Otto Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    Otto Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary Otto Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the ope …
  • Black Stone Minerals LP (BSM):石油・ガス:M&Aディール及び事業提携情報
    Summary Black Stone Minerals LP (Black Stone) is a mining and minerals exploration and development company that explores and produces mineral deposits. The company's services include participating on a working interest basis when economics are favorable, leasing minerals to exploration and productio …
  • SaskEnergy Incorporated:企業の戦略的SWOT分析
    SaskEnergy Incorporated - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Northern Power Systems Corp (NPS):企業の財務・戦略的SWOT分析
    Summary Northern Power Systems Corp (NPS), formerly Mira III Acquisition Corp is a renewable energy company that offers engineering solutions to energy sector. The company's products comprise wind turbines, power converters, microgrids, power technology products and others. It offers services such a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆